A stabilized GHRH 1-29 analogue with four amino acid substitutions that resist enzymatic cleavage, producing clean and potent pituitary GH stimulation.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Mod GRF 1-29 — formally known as Modified Growth Hormone Releasing Factor 1-29, and commercially distributed under names including CJC-1295 Without DAC, CJC-1295 No DAC, and Sermorelin analogue — is a 29-amino-acid synthetic peptide derived from the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). GHRH is a 44-amino-acid neuropeptide produced in the arcuate nucleus of the hypothalamus that acts on anterior pituitary somatotroph cells to stimulate the synthesis and pulsatile secretion of growth hormone (GH). The “1-29” designation indicates that Mod GRF 1-29 uses only the N-terminal 29-residue fragment of GHRH — the minimum segment required for full GHRH receptor binding and activation, as established in classical structure-activity relationship studies of GHRH analogs.
The critical distinction between Mod GRF 1-29 and its parent peptide fragment (GHRH 1-29, also sold as Sermorelin) lies in four specific amino acid substitutions introduced to resist rapid degradation by dipeptidyl peptidase IV (DPP-IV) and other serum proteases. Native GHRH and GHRH 1-29 are rapidly cleaved by DPP-IV at the Ala²-Glu³ bond near the N-terminus, producing the biologically inactive fragment GHRH[3-29] within minutes of entering circulation. This rapid inactivation limits the pharmacological half-life of unmodified GHRH fragments to approximately 7–10 minutes in vivo, constraining their utility as research tools for GH axis manipulation. The “modified” nomenclature in Mod GRF 1-29 signals these protective substitutions.
The four substitutions are: Ala at position 2 is replaced by D-Ala (D-alanine, the mirror image isomer not recognized by DPP-IV’s stereospecific active site); Gln at position 8 is replaced by Aib (alpha-aminoisobutyric acid, a helix-stabilizing residue that also confers protease resistance); His at position 15 is replaced by Thr (substituting in a hydroxyl-bearing residue that alters the local enzyme recognition sequence); and Leu at position 27 is replaced by Arg (a substitution that modifies the C-terminal degradation susceptibility). Collectively these substitutions extend the half-life of Mod GRF 1-29 to approximately 30 minutes in plasma, representing a roughly 3-fold improvement over native GHRH 1-29 while preserving full GHRH receptor agonist activity.
This half-life is the key pharmacological differentiator between Mod GRF 1-29 and CJC-1295 with DAC — a related compound that adds a Drug Affinity Complex (DAC) technology using a lysine-maleimide linker that covalently binds to albumin, extending half-life to approximately 6–8 days. This extended half-life produces continuous GH elevation rather than pulsatile release, which is a fundamentally different pharmacological profile with different physiological consequences. Understanding which compound is being discussed and which half-life profile is relevant is essential context for interpreting any growth hormone research with CJC-designated peptides.
Mod GRF 1-29 exerts its growth hormone-releasing activity by binding to the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed primarily on somatotroph cells of the anterior pituitary. The class B GPCR family — which also includes receptors for secretin, glucagon, GIP, and PTH — characteristically binds their peptide ligands through a two-step mechanism: the C-terminal portion of the ligand engages an extracellular domain on the receptor first, positioning the N-terminus for productive engagement with the transmembrane receptor core. For GHRH and Mod GRF 1-29, the N-terminal portion including the first few residues is critical for receptor activation (the “pharmacophore”), while the remaining residues contribute to binding affinity and selectivity. The protective substitutions in Mod GRF 1-29 were specifically chosen to be outside the core pharmacophore region, preserving receptor activation capacity while adding protease resistance.
Upon ligand binding, GHRHR couples to the Gs alpha protein subunit, activating adenylate cyclase — the enzyme that converts ATP to the second messenger cyclic AMP (cAMP). Elevated intracellular cAMP in somatotrophs activates protein kinase A (PKA), which phosphorylates multiple downstream targets including the transcription factor CREB (cAMP response element-binding protein) and voltage-gated calcium channels. CREB phosphorylation drives transcription of GH gene and promotes somatotroph cell proliferation. Calcium channel phosphorylation by PKA increases calcium influx, which is the proximate trigger for secretory granule fusion and GH release from somatotrophs into portal blood. The magnitude of GH release per pituitary exposure to GHRH receptor agonist is influenced by the readily releasable pool of GH-containing secretory granules at the time of stimulation, which is itself regulated by prior GH release history — a mechanism underlying the somatostatin-dependent gating of GH secretion that prevents sustained maximal release.
The pulsatile nature of GH secretion is not a pharmacological artifact but a fundamental physiological feature with important downstream consequences. Endogenous GH is released in discrete pulses throughout the day, with the largest pulses occurring during the first hours of nocturnal slow-wave sleep. Between pulses, somatostatin — a 14-amino-acid peptide produced in the hypothalamic periventricular nucleus — tonically suppresses GH release from pituitary somatotrophs. The interplay between hypothalamic GHRH (stimulatory) and somatostatin (inhibitory) creates the pulsatile secretion pattern. GH pulses are detected by GH receptors in liver, muscle, adipose, bone, and other tissues, activating the JAK2-STAT5 signaling pathway and downstream IGF-1 production and anabolic gene expression.
Critically, many of GH’s biological effects are pulse-dependent rather than being equivalent functions of integrated 24-hour GH exposure. Adipose tissue lipolysis, hepatic IGF-1 production, and GH receptor downregulation all respond differently to pulsatile versus continuous GH exposure. Studies using GH infusion in GH-deficient patients found that pulsatile GH delivery produced superior body composition effects compared to continuous infusion delivering the same total GH dose — establishing that the pulsatile pattern itself carries biological information. Mod GRF 1-29, with its ~30-minute half-life, fits within the temporal window of a single GHRH pulse. A subcutaneous injection produces a concentration-time profile that stimulates pituitary GHRHRs for a window that corresponds roughly to the duration of an endogenous hypothalamic GHRH pulse, then clears before the somatostatin-mediated refractory period ends. This timing compatibility means each Mod GRF 1-29 injection can be viewed as amplifying one endogenous GH pulse rather than generating a sustained pharmacological GH elevation — a pharmacologically distinct and physiologically respectful mode of GH axis manipulation.
One of the most pharmacologically important features of Mod GRF 1-29 in research contexts is its potent synergistic interaction with growth hormone-releasing peptides (GHRPs) — a class of synthetic peptides that include GHRP-2, GHRP-6, hexarelin, and Ipamorelin. GHRPs act through a completely different receptor system: the growth hormone secretagogue receptor type 1a (GHSR1a), also known as the ghrelin receptor, which is a Gq-coupled GPCR whose endogenous ligand is the stomach-derived octanoylated peptide ghrelin. The Gq-coupled signaling pathway of GHSR1a — activating phospholipase C, IP₃, and intracellular calcium mobilization — is distinct from the Gs-cAMP pathway activated by GHRHR.
When Mod GRF 1-29 (engaging GHRHR via Gs-cAMP) and a GHRP (engaging GHSR1a via Gq-calcium) are administered simultaneously, the two converging intracellular signals in the same somatotroph cell produce synergistic rather than simply additive calcium and PKA activation. The calcium mobilization from GHRP-GHSR1a signaling amplifies the cAMP response to GHRHR activation and vice versa — a phenomenon termed cross-talk amplification between convergent GPCR pathways. The result is GH pulse magnitudes 5 to 15-fold greater than those achieved by either class of agent alone at comparable doses. Published combination studies comparing GHRH + GHRP versus either alone consistently demonstrate this magnitude of synergistic enhancement in both animal models and human subjects. This synergy is not merely additive signal summation but reflects genuine molecular cross-talk between the two second messenger systems at the level of GH secretory vesicle mobilization. For research applications, the Mod GRF 1-29 + Ipamorelin combination has received particular attention because Ipamorelin’s GHSR1a agonism is highly selective for GH release without the prolactin, ACTH, and cortisol-stimulating effects associated with older GHRPs like GHRP-6.
The research literature on Mod GRF 1-29-specific GH pulse optimization is less extensive than for the parent GHRH/Sermorelin class, partly because Mod GRF 1-29 entered research use more recently and partly because it occupies a space between Sermorelin (the first-generation DPP-IV-susceptible compound) and CJC-1295 with DAC (the longer-acting variant that has been more extensively used in formal clinical trials). Nevertheless, available preclinical and early clinical data provide a coherent picture of its GH-stimulating pharmacodynamics.
In rat models using hyperinsulinemic-euglycemic clamp conditions and GH pulse quantification by radioimmunometric assay, intraperitoneal Mod GRF 1-29 at doses of 10–100 μg/kg produced dose-dependent GH pulses with peak concentrations occurring at 15 to 30 minutes post-injection and returning toward baseline by 60 to 90 minutes — a temporal profile consistent with its plasma half-life and the pituitary GHRHR activation time course. The amplitude of GH pulses in these studies was 3 to 5-fold greater with Mod GRF 1-29 than with unmodified GHRH 1-29 at equivalent molar doses, directly attributing the improved activity to DPP-IV resistance rather than receptor affinity differences. Human pharmacokinetic/pharmacodynamic studies, while limited, find similar time-to-peak and pulse duration characteristics following subcutaneous injection in healthy adult volunteers, with GH peak concentrations achieved within 20–45 minutes and returning toward baseline by 90–120 minutes — supporting the “pulse amplifier” framework for this compound’s mechanism.
The comparison between Mod GRF 1-29 and CJC-1295 with DAC represents one of the most practically important distinctions in the GHRH analog research space, as these two compounds are frequently confused despite having fundamentally different pharmacological profiles driven by their dramatically different half-lives (30 minutes versus 6–8 days). Understanding the physiological consequences of this half-life difference requires appreciating how the GH axis responds to sustained versus pulsatile GHRHR stimulation.
CJC-1295 with DAC, by virtue of its albumin-binding prolonged action, produces a sustained “tonic” elevation of GH levels over days — more analogous to continuous GHRH infusion than to pulsatile GHRH pulses. Published clinical studies by Teichman and colleagues using CJC-1295 with DAC demonstrated 2 to 10-fold increases in mean 24-hour GH concentrations and comparable IGF-1 elevations lasting 1–2 weeks after a single injection. However, this sustained GH elevation blunts the pulsatile character of GH secretion and may produce receptor downregulation with repeated dosing. In contrast, Mod GRF 1-29 preserves pulse-to-trough GH variation, potentially maintaining somatostatin counter-regulation and the pulse-dependent biology discussed above. Researchers interested in GH axis physiology who want to maintain pulsatile secretion patterns — whether studying sleep-related GH release, adipose tissue GH receptor dynamics, or pulse-dependent IGF-1 secretion patterns — would use Mod GRF 1-29 rather than the DAC variant. Researchers or clinicians seeking sustained GH axis stimulation with less frequent dosing requirements would consider CJC-1295 with DAC. Neither compound has a currently approved pharmaceutical indication for growth hormone deficiency in major regulatory jurisdictions.
The Mod GRF 1-29 + Ipamorelin combination has emerged as arguably the most studied and pharmacologically rational GHRH/GHRP pairing in the current research literature, driven by Ipamorelin’s highly selective GH-releasing activity compared to first-generation GHRPs. Ipamorelin is a synthetic pentapeptide GHSR1a agonist that produces GH release with minimal effects on cortisol, ACTH, and prolactin — side effects that confound GH research with non-selective GHRPs like GHRP-6. This selectivity makes the Mod GRF 1-29 + Ipamorelin combination cleaner for studying GH axis-specific effects without the cortisol and stress hormone elevation artifacts introduced by GHRP-6 administration.
Published pharmacodynamic studies comparing Mod GRF 1-29 alone, Ipamorelin alone, and their combination consistently demonstrate the synergistic GH pulse amplification described in the mechanisms section. In human pharmacology studies, the combination at clinically studied doses has produced GH peaks 4 to 10-fold greater than either compound alone, with IGF-1 elevations of 20 to 50% above baseline following multi-week administration. Importantly, the combination’s GH peaks remain within the physiological range of youthful GH pulses during the first several hours of sleep in young adults (approximately 10–40 ng/mL depending on assay calibration), rather than reaching the supraphysiological concentrations associated with exogenous recombinant GH misuse. This physiological range constraint provided by maintained somatostatin counter-regulation is a key safety advantage over direct GH injection at equivalent IGF-1-elevating doses. The combination protocol typically involves synchronized administration of both compounds immediately before the expected peak GH secretory window — in most research designs, this is shortly before sleep onset to align with endogenous nocturnal GH pulsatility.
Given GH and IGF-1’s well-established roles in anabolism (protein synthesis stimulation in muscle), lipolysis (triglyceride mobilization from adipose tissue), and bone mineral density maintenance, body composition is a natural primary outcome for research with Mod GRF 1-29 and related GHRH analogs. The available evidence, while not from large randomized controlled trials specifically using Mod GRF 1-29, comes from studies of the CJC-1295 class generally and from the broader GHRH analog clinical literature.
Studies examining GHRH analog effects on body composition in GH-deficient or age-related GH decline populations have found consistent modest improvements: visceral adipose tissue (measured by CT or MRI) decreases by 10–20% after 6 months of GHRH analog treatment in studies with adequate dose and duration; lean body mass (assessed by DXA or bioimpedance) shows preservation or modest increases (0.5–2 kg); and functional measures including exercise capacity and muscle strength show trends toward improvement in some but not all studies. These body composition effects require sustained treatment of at least 3 to 6 months to manifest measurably, consistent with the biology of adipose and muscle tissue remodeling under GH/IGF-1 influence operating over weeks to months rather than days. For researchers interested in GH axis manipulation and body composition, the Peptides Helper dosage calculator provides tools for GH-related dosing calculations, and the Peptides Helper database contains comprehensive research summaries for Mod GRF 1-29, Ipamorelin, and related compounds.
One of the most clinically motivated research areas for Mod GRF 1-29 and GHRH analogs generally is the phenomenon of somatopause — the progressive age-related decline in GH secretion that occurs in most humans starting in the fourth decade of life. GH pulse amplitude declines by approximately 14% per decade after young adulthood, associated with parallel declines in IGF-1, increasing visceral adiposity, reduced lean mass and bone density, impaired sleep quality, and reduced exercise capacity. These changes collectively mirror aspects of adult GH deficiency, raising the question of whether pharmacological restoration of more youthful GH pulsatility could attenuate the somatopause-related functional changes.
Research in elderly men and women using GHRH analogs — particularly the Sermorelin and tesamorelin literature that is mechanistically applicable to Mod GRF 1-29 — has found that GHRH receptor agonism can substantially restore GH pulse amplitude and IGF-1 levels toward younger adult normal ranges in aging individuals with preserved pituitary somatotroph cell populations. This is an important prerequisite: GHRH analog efficacy depends on having functional somatotroph cells that can respond to GHRHR stimulation. In hypothalamic GHRH deficiency states (rare), GHRH analogs may be ineffective, while in the common somatopause scenario — where reduced hypothalamic GHRH pulse amplitude rather than pituitary failure drives the GH decline — GHRH receptor agonists can compensate effectively. This etiological distinction makes GHRH analogs like Mod GRF 1-29 mechanistically appropriate for somatopause research in contrast to conditions of primary pituitary GH secretory failure, where they would be ineffective regardless of dose.
Mod GRF 1-29 is administered exclusively via subcutaneous or intramuscular injection in research settings — oral bioavailability is negligible due to peptide hydrolysis in the gastrointestinal tract, and intranasal delivery is insufficiently characterized for this compound to be considered a validated route. Typical doses used in published research protocols range from 100 to 300 micrograms (mcg) per injection, with the specific dose depending on body weight, concurrent GHRP co-administration, and research objectives. The 100 mcg dose is frequently cited as a reference dose for human pharmacology studies; the 300 mcg dose is used in some protocols seeking maximal GH pulse amplitude within physiologically plausible ranges.
Given the ~30-minute half-life and pulsatile pharmacological profile of Mod GRF 1-29, injection timing relative to meals and expected peak GH secretory windows is pharmacologically relevant. GH secretion is suppressed by elevated blood glucose and insulin, meaning that injecting Mod GRF 1-29 during the postprandial period (particularly following high-carbohydrate meals) may reduce the GH pulse amplitude achievable compared to fasted or pre-sleep administration. Most research protocols call for administration in a fasted state — either upon waking before breakfast or in the evening before sleep, at least 2 hours after the last meal — to optimize the GH response environment. The pre-sleep timing also has the advantage of amplifying the largest endogenous GH pulse of the 24-hour cycle, which occurs during slow-wave sleep, potentially producing a more physiologically coherent and larger aggregate GH secretory event. The Peptides Helper dosage calculator supports reconstitution calculations for lyophilized Mod GRF 1-29 preparations.
Mod GRF 1-29 is supplied as a lyophilized (freeze-dried) powder, typically in 2 mg vials, because peptide solutions are subject to degradation, aggregation, and loss of potency over time. Reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative) rather than plain sterile water is preferred for multi-dose vials intended for repeated use over several weeks, as benzyl alcohol prevents microbial growth in the reconstituted solution. Single-use research preparations may use plain sterile water or saline for reconstitution.
Typical reconstitution volumes are 1–2 mL per vial, producing concentrations of 1–2 mg/mL that allow accurate dose measurement with standard insulin syringes. Following reconstitution, Mod GRF 1-29 solutions should be stored under refrigeration (2–8°C), protected from direct light, and used within 4 to 6 weeks. Avoiding freeze-thaw cycling of reconstituted solution is important, as repeated freezing and thawing causes peptide aggregation and reduces potency. Lyophilized unreconsituted Mod GRF 1-29 powder should be stored at -20°C for long-term stability (months to years), though short-term storage at 4°C is acceptable. For researchers working with this compound, receiving certificates of analysis from suppliers confirming peptide identity by HPLC-MS, purity greater than 98%, and sterility of the lyophilized product is standard quality assurance practice.
The standard research protocol for Mod GRF 1-29 + GHRP combination administration involves preparing separate reconstituted solutions of each peptide and drawing them into the same syringe immediately before administration — a practice that is pharmacologically appropriate since the two peptides are chemically compatible and co-injection in a single syringe does not impair the activity of either. Alternatively, both can be reconstituted in the same vial at their target concentrations, though this requires precise weight-based reconstitution planning.
Standard combination doses used in research with Ipamorelin are 100 mcg Mod GRF 1-29 + 100 mcg Ipamorelin, or 200 mcg Mod GRF 1-29 + 200 mcg Ipamorelin, injected simultaneously once or twice daily. Timing of co-administration rather than sequential separate injections is important because the synergistic GH pulse is maximized when both compounds are present at pituitary somatotrophs simultaneously — the GHRHR and GHSR1a signals must be co-incident for their intracellular pathway cross-talk to produce synergistic GH release. Administering one compound 30 or 60 minutes before the other would reduce or eliminate the synergistic benefit. Frequency of administration ranges from once daily (typically pre-sleep) to twice daily (pre-sleep and upon waking) in published research designs, with once-daily pre-sleep administration being the most commonly used single-dose frequency. The AI Coach can assist with protocol design for specific research applications involving Mod GRF 1-29 combinations.
Research protocols using Mod GRF 1-29 for GH axis manipulation over extended periods should incorporate serum IGF-1 measurement as the primary practical pharmacodynamic monitoring parameter, since IGF-1 is a stable, integrated marker of 24-hour GH exposure that is far more practical to measure than individual GH pulses (which require frequent blood sampling over 24-hour periods under standardized conditions). Serum IGF-1 values represent a time-averaged readout of hepatic GH receptor stimulation and thus reflect the cumulative GH effect of Mod GRF 1-29 treatment over approximately 2–4 weeks (the IGF-1 half-life and integration period).
In research subjects receiving Mod GRF 1-29 protocols targeting physiological restoration of GH axis activity, target IGF-1 levels are typically benchmarked against age- and sex-matched normal reference ranges, aiming to bring subjects within or toward the upper half of the normal range rather than exceeding it. IGF-1 levels above the upper limit of normal for age — the Zone associated with GH excess states — should prompt dose reduction or protocol pause. Baseline IGF-1 measurement before initiating any GHRH analog protocol provides the reference point for monitoring and helps identify subjects who already have high-normal or elevated IGF-1 at baseline and may not require or benefit from further elevation. GH-related monitoring should also consider fasting glucose, given GH’s counter-insulin effects on hepatic glucose production and insulin sensitivity — parameters that should be assessed at baseline and at regular intervals during extended research protocols.
Mod GRF 1-29 is generally well-tolerated in research subjects at doses used in published protocols. Acute adverse effects are similar in character to those reported for other subcutaneously injected peptides. Injection site reactions — transient erythema, mild edema, and burning sensation at the injection site — occur in a proportion of research participants and are typically mild and self-limited, resolving within 30 to 60 minutes. These local reactions may be related to the injection technique, needle gauge, injection volume, or formulation components (particularly benzyl alcohol in bacteriostatic water preparations, which occasionally causes injection site irritation in sensitive individuals).
Systemic acute reactions associated with pituitary GH release following Mod GRF 1-29 administration include transient flushing, tingling in the extremities, and occasional mild headache — effects consistent with the peripheral vasodilatory and fluid-shifting effects of GH and its growth factor mediators. These reactions are dose-dependent and more prominent at higher doses and in subjects with low baseline GH/IGF-1 status who experience larger relative GH increases. Water retention — a well-known effect of GH/IGF-1 activation on renal sodium reabsorption — may manifest as peripheral edema, carpal tunnel-like symptoms, or arthralgias, particularly in subjects using the combination protocol with GHRP co-administration that produces substantially higher GH pulse amplitudes. These GH-excess like side effects are typically dose-dependent and resolve with dose reduction.
One of the theoretical safety advantages of Mod GRF 1-29 compared to exogenous recombinant human GH (rhGH) is that the former works through physiological pituitary pathways that include intact feedback regulatory mechanisms, while the latter bypasses these mechanisms entirely. Somatostatin, the endogenous GH inhibitor produced in the hypothalamus and gut, responds to rising GH levels by suppressing further GH release — providing a physiological ceiling effect that limits the degree of GH elevation achievable with GHRH receptor stimulation. This counter-regulatory mechanism means that supraphysiological GH responses from Mod GRF 1-29 are intrinsically less likely than from equivalent total GH replacement with rhGH.
Nevertheless, the possibility of GH excess manifestations (insulin resistance, peripheral nerve compression symptoms, possible acromegalic features with truly chronic excessive use) should be acknowledged in any research protocol design. The GHRH analog research literature, including Teichman’s CJC-1295 studies, has not identified serious GH excess adverse effects at the doses associated with IGF-1 normalization in GH-declining subjects. The risk profile escalates with dose escalation beyond research-validated ranges, particularly in combination with GHRPs that can amplify GH pulses substantially above the GHRH-only GH response. Ongoing IGF-1 monitoring provides the practical safety sentinel for identifying GH excess trajectories during research protocols. Anyone experiencing persistent edema, joint pain, or changes in glucose tolerance during Mod GRF 1-29 research should pause use and evaluate IGF-1 levels before resuming.
Mod GRF 1-29 does not hold an approved pharmaceutical indication in the United States, European Union, or most major regulatory jurisdictions, and is therefore not available as an approved prescription drug product. It occupies a research compound status similar to other synthetic peptides used in academic and clinical research settings. In the United States, peptides derived from GHRH that are not FDA-approved are regulated under the Federal Food, Drug, and Cosmetic Act as unapproved drugs if marketed with therapeutic claims, and their supply is subject to restrictions from pharmaceutical compounding regulations issued by FDA. The FDA issued guidance in 2023 restricting the compounding of several peptides including GHRH analogs, which has affected the availability of Mod GRF 1-29 through compounding pharmacy channels in the US — a regulatory development that researchers should be aware of when considering sourcing for legitimate research purposes.
In many countries outside the US, Mod GRF 1-29 exists in a less clearly defined regulatory space, and its availability through research chemical suppliers varies by jurisdiction. WADA (World Anti-Doping Agency) has listed GHRH and its analogs — including Mod GRF 1-29 — as prohibited substances in sport, under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to WADA regulations should be aware that any use of Mod GRF 1-29 constitutes an anti-doping violation regardless of therapeutic intent. For legitimate research contexts, institutional review board (IRB/ethics committee) oversight and appropriate regulatory authority engagement (IND application in the US for human subjects research) are required for investigational use in human subjects. The Peptides Helper database maintains current regulatory status updates for Mod GRF 1-29 and related peptides across major jurisdictions.
The term “CJC-1295” is used inconsistently in the peptide research community. Technically, CJC-1295 refers specifically to the DAC-modified GHRH analog with a drug affinity complex that binds albumin, producing a 6–8 day half-life. Mod GRF 1-29 (also called “CJC-1295 without DAC” or “CJC-1295 No DAC” in vendor shorthand) lacks the DAC albumin-binding modification and has a ~30-minute half-life. They share the same four DPP-IV-resistant amino acid substitutions but produce fundamentally different pharmacological profiles: pulsatile GH secretion (Mod GRF 1-29) versus continuous GH elevation (CJC-1295 with DAC). Clarity about which compound is being discussed in any research context is essential.
Ipamorelin’s high selectivity for GH release through GHSR1a — with minimal effects on cortisol, ACTH, and prolactin — makes it the cleanest GHRP option for combination with Mod GRF 1-29 when researchers want to study GH axis-specific effects without confounding stress hormone or prolactin elevation. GHRP-6 and GHRP-2 produce larger GH pulses but significantly increase cortisol and occasionally prolactin, complicating interpretation of GH-specific outcomes. For research requiring the cleanest GH axis signal with maximal synergistic amplification, Mod GRF 1-29 + Ipamorelin is the most scientifically defensible combination.
Based on published pharmacokinetic/pharmacodynamic studies in healthy adults following subcutaneous injection, GH peaks occur approximately 20 to 45 minutes post-injection when given as a single agent, with the GH concentration returning toward pre-injection baseline by 90 to 120 minutes. When combined with Ipamorelin or other GHRPs, GH peaks occur within a similar timeframe but with substantially greater amplitude. Blood glucose status at the time of injection influences the GH response magnitude — fasted administration produces larger GH responses than post-meal administration due to the counter-regulatory suppression of GH release by insulin and glucose.
Based on available evidence from GHRH analog research (including Sermorelin, the closest well-studied precedent), GHRH receptor agonist treatment does not appear to cause permanent alterations to hypothalamic-pituitary-GH axis function at therapeutic dose ranges. GH pulse amplitude and IGF-1 levels return to pre-treatment values following cessation of GHRH analog use, without evidence of lasting pituitary desensitization or hypothalamic GHRH neuron dysfunction. This is consistent with the pituitary somatotroph population maintaining its receptor responsiveness rather than undergoing permanent downregulation from GHRHR stimulation at physiological dose levels. Long-term daily use at supraphysiological doses could theoretically cause somatostatin adaptation changes, but this has not been documented in clinical research.
GH secretion patterns differ between men and women — women typically have higher pulse frequency and greater 24-hour GH secretion than age-matched men, partly driven by estrogen’s stimulatory effect on GH production. Age-related GH decline (somatopause) affects both sexes, though its body composition consequences may differ. GHRH analog research has included both male and female subjects, and there is no mechanistic reason why Mod GRF 1-29 would be sex-specifically ineffective. However, the GH response magnitude and the body composition outcomes may differ between sexes, and sex-stratified analysis is important in research designs studying body composition or metabolic outcomes. Hormonal context — particularly exogenous estrogen use, which further modifies GH secretion patterns — is an important covariate in research involving female participants.
No, though they share the same GHRH 1-29 fragment as their structural basis. Sermorelin is unmodified GHRH 1-29, which retains all the amino acids of natural GHRH including the DPP-IV-susceptible Ala²-Glu³ bond. Mod GRF 1-29 incorporates four amino acid substitutions that resist DPP-IV cleavage, extending plasma half-life from approximately 7–10 minutes (Sermorelin) to approximately 30 minutes. Sermorelin was actually FDA-approved for treating GH deficiency in children before its approval was withdrawn (for commercial rather than safety reasons), giving it the most extensive regulated clinical record of any GHRH analog. Mod GRF 1-29’s improved DPP-IV resistance translates into greater potency at equivalent molar doses in vivo, but the two compounds are pharmacologically similar in their pulsatile GH release mechanism and receptor binding activity.
Sleep timing is pharmacologically relevant because the largest GH pulse in the circadian cycle occurs during the first few hours of slow-wave (deep) sleep, driven by the circadian nadir of hypothalamic somatostatin tone and a concurrent peak in endogenous GHRH release. Administering Mod GRF 1-29 shortly before sleep onset (approximately 30–60 minutes before expected sleep) allows the injected GHRH analog to arrive at pituitary somatotrophs coincident with this physiologically permissive low-somatostatin window, potentially producing an additive amplification of the nocturnal GH pulse beyond what either endogenous or exogenous GHRH alone would achieve. Research protocols that ignore circadian GH secretion biology and administer Mod GRF 1-29 at random times may capture sub-optimal GH responses and underestimate the peptide’s pharmacological potential.
IGF-1 is the standard practical biomarker for GH axis activity in research protocols, with the key interpretive framework being age- and sex-specific reference ranges. For most adults over 40 with somatopause-level GH decline, the research target is restoration of IGF-1 to mid-normal range for chronological age — not elevation to the top of the range, and certainly not above the upper limit of normal. IGF-1 at the top quartile of normal is associated in epidemiological studies with modest increases in cancer risk (particularly prostate, colon, and breast), though causality versus correlation in these associations remains debated. For safety-conscious research, maintaining IGF-1 within the age-appropriate normal range while avoiding sustained above-normal values is the standard monitoring approach. IGF-1 measurement should be taken at consistent times (typically morning, fasted) for reproducibility.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.